2025-04-15
1. Summary of the Week
From April 7 to 11, a total of 12 biopharma deals were signed globally. Within China’s biotech industry, there were 2 out-licensing deals, 1 in-licensing deal, and 3 domestic deals.
The leading out-licensing deal was between Hengrui Pharmaceuticals and Merck KGaA for SHR7280, with an upfront payment of $16 million. The top domestic deal was between Shandong Kangzhonghong Medical and Pientzehuang Pharmaceutical for WenFeiDingChuan, valued at $2 million.
Globally, six international deals were signed during the week. The most significant was between ABL Bio and GSK for the Grabody-B platform technology, with a total deal value of $2.7 billion and an upfront payment of $49 million.
2025年4月7-11日，全球医药市场共签署了12项资产授权和合作协议。中国市场共达成6项交易，包括2项出海交易、1项引进交易和3项国内交易。
本周最大的出海交易是恒瑞医药向Merck KGaA授权一款口服GnRH受体拮抗剂SHR7280，首付款1600万美元。本周最大的国内交易是片仔癀收购山东康众宏一款中药新药“温肺定喘颗粒”，交易金额200万美元。
国际市场上，本周共签署了6项资产授权和合作协议。最大的一笔交易是GSK与ABL Bio就Grabody-B技术平台达成的全球许可协议，首付款4900万美元，总金额27亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of 20a25
4. 2019-2024 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, the YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China’s cross-border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
ACCESS CHINA
Event Name:
2025-06 ACCESS CHINA @ Boston Forum, Boston
BioToChina.org 